Hubei Guangji Pharmaceutical Co., Ltd. (SHE:000952)
China · Delayed Price · Currency is CNY 7.72
+0.04 (0.52%)
Feb 3, 2026, 3:04 PM CST
SHE:000952 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 602.13 | 635.05 | 730.11 | 794.85 | 785.1 | 686.91 |
Other Revenue | 3.75 | 3.75 | 7.71 | 2.79 | 0.47 | 1.26 |
| 605.87 | 638.8 | 737.82 | 797.64 | 785.57 | 688.17 | |
Revenue Growth (YoY) | -10.57% | -13.42% | -7.50% | 1.54% | 14.15% | -5.90% |
Cost of Revenue | 471.98 | 524.77 | 549.89 | 510.22 | 487.42 | 413.75 |
Gross Profit | 133.89 | 114.03 | 187.93 | 287.42 | 298.15 | 274.42 |
Selling, General & Admin | 252.57 | 263.03 | 194.83 | 149.94 | 137.29 | 138.52 |
Research & Development | 44.47 | 56.82 | 74.75 | 68.98 | 52.06 | 38.77 |
Other Operating Expenses | 30.05 | 14.03 | 12.92 | 13.5 | 15.97 | 13 |
Operating Expenses | 322.93 | 331.08 | 282.64 | 236.3 | 210.87 | 190.44 |
Operating Income | -189.04 | -217.04 | -94.7 | 51.13 | 87.28 | 83.97 |
Interest Expense | -54.9 | -61.98 | -49.15 | -21.1 | -16.71 | -31.95 |
Interest & Investment Income | 19.97 | 2.06 | 3.46 | 8.31 | 21.95 | 33.58 |
Currency Exchange Gain (Loss) | 4.31 | 4.31 | 2.07 | 4.33 | -2.11 | -5.66 |
Other Non Operating Income (Expenses) | -2.81 | -0.38 | -0.04 | -1.01 | 7.3 | -0.96 |
EBT Excluding Unusual Items | -222.46 | -273.03 | -138.36 | 41.65 | 97.72 | 78.98 |
Gain (Loss) on Sale of Investments | -24.28 | -27.92 | -10.02 | - | - | - |
Gain (Loss) on Sale of Assets | -2.4 | -2.4 | 0.25 | -4.31 | 0.54 | 0.18 |
Asset Writedown | -26.05 | -30.68 | -0.12 | -0.14 | -0.01 | -0.46 |
Legal Settlements | 1.04 | 1.04 | 0.9 | -0.75 | 5.55 | -5.55 |
Other Unusual Items | 17.87 | 12.71 | 6.69 | 23.63 | 20.54 | 15 |
Pretax Income | -256.28 | -320.29 | -140.67 | 60.08 | 124.34 | 88.15 |
Income Tax Expense | -6.58 | -5.16 | 11.75 | 12.4 | 18.53 | 17.85 |
Earnings From Continuing Operations | -249.71 | -315.13 | -152.41 | 47.68 | 105.81 | 70.3 |
Minority Interest in Earnings | 15.69 | 19.84 | 12.17 | 2.65 | 4.3 | 4.35 |
Net Income | -234.01 | -295.29 | -140.25 | 50.33 | 110.11 | 74.65 |
Net Income to Common | -234.01 | -295.29 | -140.25 | 50.33 | 110.11 | 74.65 |
Net Income Growth | - | - | - | -54.29% | 47.50% | -14.14% |
Shares Outstanding (Basic) | 349 | 352 | 354 | 351 | 344 | 334 |
Shares Outstanding (Diluted) | 349 | 352 | 354 | 353 | 344 | 334 |
Shares Change (YoY) | -1.07% | -0.60% | 0.36% | 2.54% | 2.85% | 9.28% |
EPS (Basic) | -0.67 | -0.84 | -0.40 | 0.14 | 0.32 | 0.22 |
EPS (Diluted) | -0.67 | -0.84 | -0.40 | 0.14 | 0.32 | 0.22 |
EPS Growth | - | - | - | -55.42% | 43.41% | -21.44% |
Free Cash Flow | 19.62 | -154.28 | -715.1 | -158.63 | -20.7 | 21.49 |
Free Cash Flow Per Share | 0.06 | -0.44 | -2.02 | -0.45 | -0.06 | 0.06 |
Dividend Per Share | - | - | - | - | 0.060 | 0.060 |
Dividend Growth | - | - | - | - | - | 2.92% |
Gross Margin | 22.10% | 17.85% | 25.47% | 36.03% | 37.95% | 39.88% |
Operating Margin | -31.20% | -33.98% | -12.83% | 6.41% | 11.11% | 12.20% |
Profit Margin | -38.62% | -46.23% | -19.01% | 6.31% | 14.02% | 10.85% |
Free Cash Flow Margin | 3.24% | -24.15% | -96.92% | -19.89% | -2.63% | 3.12% |
EBITDA | 9.25 | -52.84 | 24.04 | 148.58 | 178.15 | 174.42 |
EBITDA Margin | 1.53% | -8.27% | 3.26% | 18.63% | 22.68% | 25.35% |
D&A For EBITDA | 198.29 | 164.2 | 118.75 | 97.45 | 90.87 | 90.44 |
EBIT | -189.04 | -217.04 | -94.7 | 51.13 | 87.28 | 83.97 |
EBIT Margin | -31.20% | -33.98% | -12.83% | 6.41% | 11.11% | 12.20% |
Effective Tax Rate | - | - | - | 20.64% | 14.90% | 20.25% |
Revenue as Reported | 605.87 | 638.8 | 737.82 | 797.64 | 785.57 | 688.17 |
Advertising Expenses | - | 15.88 | 9.05 | 5.84 | 6.12 | 6.78 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.